Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMU-281
- Development stage
- Preclinical
- Lead developer
- De Montfort University
- Modality
- Small Molecules
01
Overview
DMU-281 (4'-hydroxy-3,4,5-trimethoxystilbene) is a methoxylated resveratrol analogue and a metabolite of DMU-212. It is being investigated for its potential as an anticancer agent, particularly in the treatment of colorectal cancer. The compound demonstrates cytotoxic activity by inducing cell cycle arrest at the G2/M phase and triggering apoptosis through both intrinsic and extrinsic pathways, evidenced by the activation of caspases-3, -7, -8, and -9. DMU-281 was designed to improve upon the poor bioavailability and pharmacokinetic limitations of resveratrol.
- Other names
- 4'-hydroxy-3,4,5-trimethoxystilbene4'-hydroxy-3,4,5-trimetoxystilbene
02
Targets
BSH (Bile salt hydrolase)
Beyond the preview
Go deeper on DMU-281.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMU-281.